12 Dec 2016 16:11
INTERNATIONAL BIOTECHNOLOGY TRUST PLC (the Company)
Â
Â
Portfolio Update as at 30 November 2016
Â
Net Assets | £229m |
Net Assets per share | 609p |
Share price | 559p |
Total value of unquoted investments | £26m |
Total number of portfolio companies | 79 |
Â
Top Ten Holdings
Â
Company Name | % NAV |
Celgene | 7.5 |
Biogen | 6.8 |
Genmab | 6.4 |
Alexion | 5.8 |
Actelion | 5.0 |
Gilead | 4.5 |
Tesaro | 4.5 |
Shire | 4.5 |
Regeneron | 4.3 |
Ariad | 3.1 |
----------- | |
Total | 52.4 |
Â
Geographical Allocation | % NAV |
US & Canada | 74 |
Europe & UK | 26 |
----------- | |
Total | 100 |
Â
Â
Quoted/Unquoted Allocation | % NAV |
Quoted | 89 |
Unquoted | 11 |
----------- | |
Total | 100 |
Â
Â
NAV % Market Cap | % NAV |
Large Cap >USD10BN | 59 |
Mid Cap =USD1-10BN | 20 |
Small Cap | 21 |
----------- | |
Total | 100 |
Â
Â
NAV % by Therapeutic Areas | % NAV |
Oncology | 35 |
Orphan | 18 |
Inflammation | 8 |
Ophthalmology | 5 |
CNS | 9 |
Medtech | 3 |
Other | 22 |
----------- | |
Total | 100 |
Â
Â
Unquoted portfolio update
The Board notes the following changes in valuation to the unquoted portfolio during November 2016:
Â
Due to a recapitalisation of NCP Holdings, the Company received proceeds of £1.2m in exchange for 47.5% of our holding. The value of the remaining holding has reduced from £2.1m to £1.7m and the net impact on the NAV was an increase of £0.8m. The sale of Atopix was finalised and we received proceeds of £0.5m on completion of the sale to Chiesi Farmaceutici. This led to an overall increase of £0.1m to NAV reflecting both the cash received and the value of future milestone payments which may be received. A milestone was received from Biogen in relation to Convergence Pharmaceuticals totalling £0.6m, an increase to the valuation of £0.1m. The valuation of Cell Medica Limited increased by £0.1m due to an increase in the expected receipt of milestones related to the sale of Delenex dermatology assets. A £0.3m increase in value of an unquoted company which cannot be named due to sensitive business development discussions which are on-going. A range of likely business development outcomes are being discussed with a further positive valuation impact of between £1.0m and £2.3m, which due to the uncertainty of the discussions have not been included in the current NAV.
Â
The net impact of these changes to the NAV was an increase of £1.4m or 3.46p per share.
Â
In addition, we note the reverse merger of Kalvista Pharmaceuticals with Carbylan completed on 22 November 2016. This investment is now listed on the Nasdaq stock exchange.
Â
BNP Paribas Secretarial Services Limited
Company Secretary
Â
12 DECEMBER 2016